Sharemaestro Newsreel

OPKO Health gives back 17% after sharp post-earnings surge (OPK:NASDAQ)

Why NeoGenomics (NEO) Stock Is Up Today

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to join …

IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for IDEXX Laboratories Inc (IDXX), detailing its volatility, financial risk, and investment risk. The company has a current risk assessment score of 7.69, ranking 31st in the Healthcare Equipment & Supplies industry, and a beta value of 1.56, …

Qiagen NV (QGEN) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Qiagen NV (QGEN)'s financial health, indicating a stable financial status and high operating efficiency with a current financial score of 8.79. The company reported a 1.83% year-over-year increase in quarterly revenue, reaching 492.32M, and a 25.03% year-over-year increase …

Danaher Corp (DHR) Institutional Confidence

Danaher Corp (DHR) has an institutional shareholding score of 7.00, placing it 78th in the Healthcare Equipment & Supplies industry. This score reflects an institutional shareholding proportion of 83.99%, which decreased by 0.84% quarter-over-quarter. The largest institutional shareholder is Al Gore, holding 7.97M shares, …

How Waters’ New Xevo IVD Mass Spectrometer Could Shape Its Clinical Diagnostics Strategy (WAT)

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance …

ATYR|aTyr Pharma Inc|Price:0.499|Chg%:+0.010

This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals …

OPK|OPKO Health Inc|Price:1.650|Chg%:+0.410

This article provides a comprehensive stock analysis of OPKO Health Inc (OPK), highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes high institutional ownership and recent "Buy" ratings from analysts, with expectations for the …

Medpace Holdings Inc (MEDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Medpace Holdings Inc (MEDP), detailing its current price momentum, support and resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, KDJ, and moving averages. …

Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Fulgent Genetics Inc (FLGT), noting its score of 6.80, which ranks 25 out of 75 in the Healthcare Providers & Services industry. The company's beta of 0.93 indicates it tends to underperform in up markets but decline …

IMUX|Immunic Inc|Price:13.271|Chg%:-0.539

This article provides a detailed stock analysis of Immunic Inc (IMUX) based on TradingKey's comprehensive stock score. It highlights Immunic's strong fundamentals and high growth potential, noting it's fairly valued within the Biotechnology & Medical Research industry. The analysis also covers high institutional ownership …

Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Veracyte Inc (VCYT), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests VCYT is suitable for range-bound swing trading, with indicators showing mixed signals …

Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Myriad Genetics (MYGN) is set to report Q2 earnings this Thursday, with analysts expecting a 2.5% year-on-year revenue decline. The company missed revenue expectations last quarter, and its stock is down 9.5% over the last month, contrasting with a 4.4% average rise in the …

Why is Solventum stock surging today?

Solventum stock surged over 7% today after UBS upgraded the healthcare company from Neutral to Buy, setting a price target of $95. This upgrade, combined with supportive analyst sentiment and an upcoming Q2 2026 earnings report on August 5, pushed Solventum shares towards their …

What To Expect From Labcorp’s (LH) Q2 Earnings

Labcorp (LH) is set to announce its Q2 earnings this Thursday. Analysts expect a 5.3% year-on-year revenue growth, a slowdown from the previous year, though the company generally met revenue expectations last quarter. Investor sentiment in the healthcare providers & services sector has been …

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28

This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their …

IQVIA Holdings (IQV) Soars on Revenue Growth Outlook, Strong Q2

IQVIA Holdings (IQV) saw its stock jump after reporting strong second-quarter results and raising its revenue growth outlook for the full year 2026. The company grew its revenues by 8.7% to $4.37 billion in Q2, contributing to an updated full-year projection of $17.275 billion …

DVA|DaVita Inc|Price:239.495|Chg%:+3.185

The article provides a comprehensive stock analysis of DaVita Inc (DVA) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes DaVita's high institutional ownership, Warren Buffett's stake, and analysts' "Hold" rating with …

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Total revenue in the quarter was $201.7 …

MDXH|MDxHealth SA|Price:0.400|Chg%:-0.011

This article provides a comprehensive stock analysis of MDxHealth SA (MDXH), highlighting its strong fundamentals and high growth potential despite recent weak market performance. The company is considered fairly valued within the Biotechnology & Medical Research industry and shows high institutional ownership. Analysts have …

Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis

Myriad Genetics Inc (MYGN) has a stable financial status and high operating efficiency, ranking 93rd out of 199 companies in the Healthcare Equipment & Supplies industry with a score of 7.30. The company reported a Q4 revenue of $200.40 million, marking a 2.30% year-over-year …

MEDP|Medpace Holdings Inc|Price:585.350|Chg%:+14.380

Medpace Holdings Inc (MEDP) closed at $585.35 on July 29, 2026, up 2.52%, with a market capitalization of $16.30 billion. The company exhibits strong fundamentals, high growth potential, and is considered fairly valued in the Biotechnology & Medical Research industry, where it ranks 65 …

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

Agilent Technologies Inc. (NYSE: A) will release its third-quarter fiscal year 2026 financial results after the market closes on Wednesday, Aug. 26. The company will host a conference call on the same day at 1:30 p.m. PDT to discuss the results, which will be …

IQVIA (IQV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

IQVIA Holdings (IQV) reported $4.37 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 8.7%. EPS of $3.15 for the same period compares to $2.81 a year ago. The reported revenue represents a surprise of +1.63% over the Zacks …

Biodesix, Inc. Revenue Breakdown – NASDAQ:BDSX

This document provides a revenue breakdown for Biodesix, Inc. (NASDAQ: BDSX), accessible through TradingView. It offers an overview of the company's financial information, including statements, statistics, dividends, earnings, and segment performance by source and country. The information is sourced from ICE Data Services, FactSet, …

Amgen Inc Stock (AMGN) Moved Up by 4.02% on Jul 28: What Signal Does It Send?

Amgen Inc (AMGN) saw a 4.02% increase in its stock price, driven by strong second-quarter earnings that surpassed estimates and positive clinical data for its obesity drug MariTide. Technical indicators suggest a buy signal, though clinical safety concerns about MariTide and high pipeline dependency …

IBIO|iBio Inc|Price:1.389|Chg%:-0.001

This article provides a comprehensive stock analysis of iBio Inc (IBIO) by TradingKey, highlighting its healthy fundamentals, high growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company exhibits strong fundamentals, very high …

IKT|Inhibikase Therapeutics Inc|Price:2.217|Chg%:-0.093

Inhibikase Therapeutics Inc (IKT) shows strong fundamentals and high growth potential, despite recent technical trends not fully supporting its performance. The company is considered fairly valued and has high institutional ownership. Analysts have given it a "Buy" rating with a target price indicating significant …

ICON Shares Rise on Anthropic Collaboration to Bring AI Across Clinical Trials

ICON plc (ICLR) saw its shares rise following an announcement of a collaboration with Anthropic, an AI safety and research company. This partnership aims to integrate Anthropic's generative AI, Claude, into ICON's clinical trial operations, enhancing efficiency, improving data analysis, and accelerating patient outcomes. …

Agilent Technologies Q3 Results: Earnings call set for Aug 26

Agilent Technologies Inc. will report its third-quarter fiscal year 2026 financial results after market close on August 26th. A conference call will follow at 1:30 p.m. PDT to discuss the company's performance and operational trends. In fiscal year 2025, Agilent Technologies generated $6.95 billion …

Revvity Inc (RVTY) Stock Up 3.2% and Still Undervalued -- GF Sco

Revvity Inc (RVTY) shares rose 3.2% to $111.51, reflecting a 15.5% year-to-date gain, yet the stock is considered 7.5% undervalued with a GF Value of $120.57. Despite an attractive valuation rank of 10/10, its growth rank is low at 3/10, and the P/E ratio …

GLMD|Galmed Pharmaceuticals Ltd|Price:0.543|Chg%:+0.009

This article provides a comprehensive stock analysis of Galmed Pharmaceuticals Ltd (GLMD), highlighting its stable fundamentals, high growth potential, and fair valuation compared to its industry peers. The company's main focus is on developing Aramchol for treating non-alcoholic steatohepatitis (NASH). Despite average recent stock …

GERN|Geron Corp|Price:1.415|Chg%:-0.035

This article provides a comprehensive stock analysis of Geron Corp (GERN) by TradingKey, highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and recent market outperformance, technical indicators suggest the stock is …

Illumina, Inc. Revenue Breakdown – LSX:927079

This article provides a revenue breakdown for Illumina, Inc. (LSX:927079), detailing its performance in the last fiscal year. The company generated 3.70 billion EUR, with its Core Illumina - Consumables segment being the top contributor at 2.75 billion EUR. Geographically, the United States was …